News | Prostate Cancer | July 19, 2021

New AI Tech for Early Detection of Prostate Cancer

Artificial intelligence-powered diagnostic tool spots asymptomatic prostate cancer in seconds

Artificial intelligence-powered diagnostic tool spots asymptomatic prostate cancer in seconds

(L-R) Associate Professor Peter Brotchie (St Vincent's), Dr Ruwan Tennakoon (RMIT), Professor John Thangarajah (RMIT), Dr Mark Page (St Vincent's). Image courtesy of St Vincent's Hospital Melbourne

July 19, 2021 — Prostate cancer is the most diagnosed cancer and a leading cause of death by cancer in Australian men. Early detection is key to successful treatment but men often dodge the doctor, avoiding diagnosis tests until it's too late.

Now an artificial intelligence (AI) program developed at RMIT University in Melbourne, Australia, could catch the disease earlier, allowing for incidental detection through routine computed tomography (CT) scans. The tech, developed in collaboration with clinicians at St Vincent's Hospital Melbourne, works by analysing CT scans for tell-tale signs of prostate cancer, something even a well-trained human eye struggles to do.

CT imaging is not suitable for regular cancer screening because of the high radiation doses involved, but the AI solution could be used to run a cancer check whenever men have their abdomen or pelvis scanned for other issues. RMIT's Ruwan Tennakoon, Ph.D.,  said CT scans were great for detecting bone and joint problems but even radiologists struggled to spot prostate cancers on the images. "We've trained our software to see what the human eye can't, with the aim of spotting prostate cancer through incidental detection," he said. "It's like training a sniffer dog - we can teach the AI to see things that we can't with our own eyes, in the same way a dog can smell things human noses can't."

Prostate cancer is slow growing and is usually detected incidentally, so can go undiagnosed for years. In 2020, it was responsible for an estimated 12% of male cancer deaths in Australia.

How it works

For the study, published in Nature's Scientific Reports, researchers from RMIT and St Vincent's Hospital Melbourne studied CT scans of asymptomatic patients, with and without prostate cancer. The team trained the AI software to look for features of disease in a variety of scans and where exactly to look for them, avoiding the need to manually crop the images. The AI performed better than radiologists who viewed the same images, detecting cancerous growths in just seconds. What's more, the AI improved with each scan, learning and adapting to read images from different machines to spot even the smallest irregularities.

RMIT's Head of Artificial Intelligence, Professor John Thangarajah, said the study demonstrated how AI can and should be used to create public good. "Our health sector needs smarter solutions and AI can help, but we're only scratching the surface," he said. "There's a lot of good that artificial intelligence can bring to the world, which is our focus at RMIT, and this study forms a big part of that."

Mark Page, M.D., Head of CT in Diagnostic Imaging at St Vincent's Hospital Melbourne, said early intervention for prostate cancer was key to a better health outcome. "Australia doesn't have a screening program for prostate cancer but armed with this technology, we hope to catch cases early in patients who are scanned for other reasons," he said. "For example, emergency patients who have CT scans could be simultaneously screened for prostate cancer. If we can detect it earlier and refer them to specialist care faster, this could make a significant difference to their prognosis."

The technology can be applied at scale, potentially integrating with a variety of diagnostic imaging equipment like MRI and DEXA machines - pending further research. "It was excellent to tap into the AI expertise at RMIT and we look forward to future possibilities for analysing more radiology scans," Page said.

The multi-disciplinary team, including researchers from RMIT's School of Engineering and School of Computing Technologies, is looking for interested commercial partners to develop software to further integrate the AI technology with hospital equipment for possible clinical trials.

For more information: www.rmit.edu.au

Find more information on prostate cancer here.

Related Content

This study shows that thanks to deep learning analysis applied to digitized pathology slides, artificial intelligence can classify patients with localized breast cancer between high risk and low risk of metastatic relapse in the next five years.

Getty Images

News | Artificial Intelligence | September 22, 2021
September 22, 2021 — The RACE AI study conducted by Gustave...
The development of new research guidelines for interventional oncology that standardize treatment outcomes and the reporting of data represents a major step forward for an increasingly important medical subspecialty, according to a report in Radiology.

Getty Images

News | Radiation Oncology | September 21, 2021
September 21, 2021 — The development of new research guidelines for interventional oncology that standardize treatmen
HealthMyne, a pioneer in applied radiomics, announced today that peer-reviewed research recently published in the journal Cancers has demonstrated the ability of its radiomics technology to identify biomarkers that predict whether patients with lung adenocarcinoma would benefit from immunotherapy.

Semi-automatic lesion identification: (A) Manual ROI indication. In blue, it is possible to observe the axes that cross the lesion manually delineated by the radiologist on a plane of the MPR. The intensity of the lesion boundary (estimated) is represented with a red outline. (B) Additional axes can be dragged onto other orthogonal MPR views. From left to right, it is possible to observe the initial long axis outlined by the radiologist and the 2D contours on the axial, coronal and sagittal views of the lesion used as a starting point for the RPM algorithms. (C) Resulting 3D contour of the lesion (in blue).

News | Radiomics | September 21, 2021
September 21, 2021 —  HealthMyne, a pioneer in applied radiomics, announced today that peer-reviewed ...
An illustration based on simulations by Rice University engineers shows a gadolinium ion (blue) in water (red and white), with inner-sphere water -- the water most affected by the gadolinium -- highlighted. The researchers’ models of gadolinium in water show there’s room for improvement in compounds used as contrast agents in clinical magnetic resonance imaging.

An illustration based on simulations by Rice University engineers shows a gadolinium ion (blue) in water (red and white), with inner-sphere water -- the water most affected by the gadolinium -- highlighted. The researchers’ models of gadolinium in water show there’s room for improvement in compounds used as contrast agents in clinical magnetic resonance imaging. Illustration by Arjun Valiya Parambathu

News | Magnetic Resonance Imaging (MRI) | September 20, 2021
September 20, 2021 — ...
Non-oncology doctors’ knowledge of oncology is frequently not up to date, with risks in the communication with patients  

Getty Images

News | Radiation Oncology | September 20, 2021
September 20, 2021 — The rapid pace of developments in the oncology field, mainly brought by cancer immunotherapy, me
News | Breast Imaging | September 20, 2021
September 20, 2021 — ImageCare Centers is unveiling its new “PINK Better Mammo” service with the addition of...
IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, and SCK CEN (Belgian Nuclear Research Center) announced a strategic R&D partnership to enable the production of Actinimum-225 (225Ac), a novel radioisotope which has significant potential in the treatment of cancer.
News | Radiation Oncology | September 17, 2021
September 17, 2021 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, a
Shimadzu Medical Systems USA, a leading manufacturer of advanced medical X-ray imaging systems, has announced that the Trinias unity edition product line has been awarded a contract from Vizient, Inc., a healthcare performance improvement company, effective Sept. 1, 2021.
News | X-Ray | September 17, 2021
September 17, 2021 — Shimadzu Medical Systems USA, a leading manufacturer of advanced medical...